Results 71 to 80 of about 103,385 (306)
Introduction Peripheral T-cell lymphoma of the unspecified variant is a highly aggressive subtype of T-cell non-Hodgkin's lymphoma. This is the first reported case of this type of lymphoma presenting as an ischemic stroke in a woman.
Fragou Mariantina +4 more
doaj +1 more source
Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients [PDF]
Monica Mead +8 more
openalex +1 more source
DEL‐1 is an Endogenous Senolytic Protein that Inhibits Senescence‐Associated Bone Loss
Senescent bone marrow stromal cells accumulate in the aging bone microenvironment, promoting bone degeneration. DEL‐1, an endogenous secreted protein, acts as a natural senolytic that selectively eliminates these cells. By engaging a β3 integrin/CD73/adenosine/p38 MAPK/BCL‐2 pathway, DEL‐1 counters aging‐related bone loss, revealing promising ...
Jong‐Hyung Lim +11 more
wiley +1 more source
Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute [PDF]
: Background: Primary cutaneous T-cell lymphomas constitute a heterogeneous and rare group of diseases with regional particularities in Latin America.
Rosana Ruiz +5 more
doaj +1 more source
Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. [PDF]
Serine-threonine kinase CK2 is highly expressed and pivotal for survival and proliferation in multiple myeloma, chronic lymphocytic leukemia and mantle cell lymphoma.
Agostinelli, C +9 more
core +1 more source
Cinnamic‐hydroxamic‐acid derivatives (CHADs) are identified as novel inhibitors of the bacterial nucleoid‐associated protein HU, exhibiting potent antibacterial, anti‐biofilm (both inhibition and eradication), and DNA relaxation (anti‐supercoiling) activities. Moreover, CHADs demonstrate strong synergistic effects with multiple antibiotics.
Huan Chen +22 more
wiley +1 more source
Objective We report the results of a pilot study investigating the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed/ refractory T‐cell lymphoma. Methods A dose escalation study design was utilized.
Carrie van der Weyden +4 more
doaj +1 more source
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao +13 more
wiley +1 more source
Peripheral T cell lymphoma: clinical utility of romidepsin
Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years.
Sawey K, Zain J
doaj
We recently reported deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Functional analyses confirmed that PTPN2 acts as classical tumor suppressor repressing the proliferation of T cells, in part through ...
Maria Kleppe +7 more
doaj +1 more source

